Cargando…
Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study
Data on long-term survival and prognostic significance of demographic factors and adverse events (AEs) associated with sorafenib, an orally administered multikinase inhibitor in Chinese population with advanced renal cell carcinoma (RCC) are limited. Outcome data from adult patients (n = 256) with a...
Autores principales: | Zhang, Hai-Liang, Qin, Xiao-Jian, Wang, Hong-Kai, Gu, Wei-Jie, Ma, Chun-Guang, Shi, Guo-Hai, Zhou, Liang-Ping, Ye, Ding-Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742216/ https://www.ncbi.nlm.nih.gov/pubmed/26472104 |
Ejemplares similares
-
Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors
por: Zhang, Hai-Liang, et al.
Publicado: (2017) -
Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma
por: Ye, Ding-Wei, et al.
Publicado: (2014) -
Eosinophil percentage elevation as a prognostic factor for overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor
por: Wang, Hong-Kai, et al.
Publicado: (2016) -
Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib With or Without Cryoablation
por: Gu, Cheng-Yuan, et al.
Publicado: (2021) -
Retrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival
por: Yu, Xiaoteng, et al.
Publicado: (2015)